Ikarisoside F Inhibitor

Solid. Powder

98.00%

Store at -20 degree C for 3 years powder
-80 degree C for 2 years in solvent

632.62

<1mg/ml refers to the product slightly soluble or insoluble

C31H36O14

C[C@@H]([C@@H]([C@H]([C@H]1O[C@@H]([C@@H]([C@H]2O)O)OC[C@H]2O)O)O)O[C@H]1OC1=C(c(cc2)ccc2O)Oc(c(CC=C(C)C)c(cc2O)O)c2C1=O

113558-14-8

Others

The results showed that Epimedium extract inhibited the activity of recombinant human AdoHcy hydrolase in a dose-dependent manner. This inhibitory effect was also observed in hepatic cell line 7701 and hepatoma HepG2, however, the effect in 7701 cells was more potent than in HepG2 cells. The extract could significantly reduce AdoMet/AdoHcy ratio in 7701 cells in a dose-dependent manner, suggesting reduced biomethylation level in 7701 cells. In contrast, it resulted in elevated AdoMet/AdoHcy ratio in the HepG2 cells. The result of MALDI-MS assay indicated that epimedin A and Ikarisoside F from the extract could bind to AdoHcy hydrolase. The present data suggested that Epimedium extract could inhibit the activity of AdoHcy hydrolase, thus regulating the cellular biomethylation as well as reducing cellular Hcy level.